Resmetirom is an oral, first, liver-directed, selective thyroid hormone receptor-beta (THR-β) agonist approved by US FDA for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
It modulates lipid metabolism and reduces hepatic steatosis and inflammation without systemic thyromimetic effects.
Resmetirom is the first and only approved drug shown to significantly reverse fibrosis in patients with MASH.
Resmetirom is indicated along with diet and exercise for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (stage F2–F3)
It reduces liver fat, stiffness and inflammation.
Plays an important role in NASH resolution and decreases liver fibrosis.
Resmetirom also improves lipid profile, including LDL-C, triglycerides, and apolipoprotein B.
It helps in improving insulin sensitivity.
Resmetirom improves cardiovascular outcomes and QoL of MASH patients.
It can be used as part of a comprehensive metabolic management plan, especially in patients with underlying
dyslipidemia, type 2 diabetes, or obesity.
Inform your doctor about your medical history of heart disease, liver/kidney disease, or blood clots and the
list of medicines you are already taking to avoid contraindications.
It should be used on doctors' prescriptions. Your doctor will prescribe the dosage depending upon your body
weight.
This medicine is generally safe with few mild side effects such as diarrhoea, nausea, abdominal pain and
dizziness.
Doctors recommend monitoring your liver health regularly while taking the medicine.
A healthy diet and regular exercise along with this medicine would be an effective treatment to reverse the
MASH.
